CAR-T cell therapy
Kymriah · Yescarta · CAR-T cell therapy
CRS-driven prerenal AKI and tumor lysis.
PREATNXTAL
ModerateOpen →
The Drug Explorer
Search the nephrotoxic landscape
A live index of 240+ anti-cancer agents, cross-filterable by injury signature, drug class, nephron segment, severity, and era. Profiled agents open to a full citation-grounded page; the rest are catalog entries with their signature kidney signal.
15 agents · filtered from 240
Profile
Cladribine
Leustatin · Purine analog
Tumor lysis; high-dose nephrotoxicity.
PREXTALLYTE
MildOpen →
Cytarabine
Cytosar · Nucleoside analog
Tumor lysis in leukemia; high-dose toxicity.
PREXTALLYTE
ModerateOpen →
Etoposide
Etopophos · Topoisomerase II inhibitor
Tumor lysis; renally cleared.
PREXTALLYTE
MildOpen →
Hydroxyurea
Hydrea · Ribonucleotide reductase inhibitor
Tumor lysis in myeloproliferative disease.
PRELYTEXTAL
MildOpen →
Ibritumomab tiuxetan
Zevalin · Radioimmunotherapy (Y-90 anti-CD20)
Yttrium-90 radioimmunotherapy; tumor lysis with bulky lymphoma.
PREXTALLYTE
MildOpen →
Idarubicin
Idamycin · Anthracycline
Tumor lysis in acute leukemia.
PREXTALLYTE
MildOpen →
Infigratinib
Truseltiq · FGFR inhibitor
Hyperphosphatemia — on-target FGFR class effect; nephrocalcinosis risk.
LYTEXTAL
ModerateOpen →
Methotrexate (high-dose)
Trexall · Antifolate
Crystal nephropathy; glucarpidase rescue.
XTALATN
ModerateOpen →
Mitoxantrone
Novantrone · Anthracenedione
Tumor lysis; low direct renal toxicity.
PREXTALLYTE
MildOpen →
Obinutuzumab
Gazyva · Anti-CD20 antibody
High tumor-lysis risk in CLL.
XTALATNPRE
ModerateOpen →
Pralatrexate
Folotyn · Antifolate
Antifolate with MTX-like renal handling.
XTALATN
ModerateOpen →
Raltitrexed
Tomudex · Antifolate (TS inhibitor)
Renally cleared antifolate; exposure ~doubles in renal impairment; forerunner CB3717 withdrawn for crystal nephrotoxicity.
ATNXTAL
ModerateOpen →
Rituximab
Rituxan · Anti-CD20 antibody
Tumor lysis with bulky disease; treats some GN.
XTALATNPRE
ModerateOpen →
Venetoclax
Venclexta · BCL-2 inhibitor
Major tumor lysis syndrome risk on ramp-up.
XTALATNPRE
SevereOpen →